Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

SPI-62 As a Treatment for Hypercortisolism Related to a Benign Adrenal Tumor

Next Previous
Trial Profile

SPI-62 As a Treatment for Hypercortisolism Related to a Benign Adrenal Tumor

Status: Discontinued
Phase of Trial: Phase II

Latest Information Update: 06 Mar 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Clofutriben (Primary)
  • Indications Adrenal gland disorders; Cushing syndrome
  • Focus Therapeutic Use
  • Acronyms ACSPIRE
  • Sponsors Sparrow Pharmaceuticals

Most Recent Events

  • 26 Feb 2025 Status changed from active, no longer recruiting to discontinued, because the continuation of this trial was not justified since the data did not demonstrate a clear benefit for this patient population.
  • 11 Dec 2024 According to a Sparrow Pharmaceuticals media release,company is collaborating with the University of Oxford and the University of Sheffield on DC-MACS, an investigator led, Phase 2 clinical study in the United Kingdom of clofutriben (SPI-62) for the treatment of autonomous cortisol secretion (ACS).
  • 30 May 2024 According to a Sparrow Pharmaceuticals media release, interim data from ongoing clinical trials in patients with ACTH-dependent Cushing's syndrome will be presented by the David Katz during SY55 - Development of Novel Endocrine Therapies by Inhibiting Steroid Biosynthesis session.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top